Castle Hill Capital Partners, Inc. (Castle Hill), a US broker/dealer offering strategic capital raising and consulting services, today announced that respected healthcare industry veteran, Tim McInerney, will join the firm as a Managing Director. McInerney, who will operate out of the NY office, will lead the firm’s entrance into private placement capital raising with a focus on healthcare opportunities.
“We are delighted to add Tim’s insight, expertise and deep, multi-year relationships to our firm. Tim is a personal investor in many companies and has a track record of success. More and more we hear from our single family office, endowment and foundation clients that they want to be closer to the source of return and increasingly opting for direct investments. Adding Tim’s experience and successful track record building healthcare companies is an exciting next step in the evolution of our firm,” commented Andrew Saunders, Senior Managing Director of Castle Hill.
“Castle Hill offers the most diversified platform of strategies and opportunities while maintaining a collaborative, entrepreneurial environment. Investing in Healthcare has historically provided superior returns. While the present investment climate has created new challenges, we believe that the space will continue to provide these potential returns to focused and selective investors,” added Tim McInerney.
Tim McInerney
Mr. McInerney brings over 30 years of experience as a pharmaceutical executive and healthcare investment banker and analyst with positions in industry and a number of Wall Street firms. Following positions at Bristol, Myers Squibb, Bear Stearns, Shearson Lehman Brothers and Ladenburg Thalmann, Mr. McInerney oversaw the overall distribution of Paramount Capital’s private equity product and was directly responsible for over $1BB in capital raised for both startups and private placement investments. In the early stage financings of Cougar Biotech (acquired by JNJ), Kite Pharma, Velcera (acquired by Perrigo) and Ziopharm Oncology, Mr. McInerney played a significant role. He has served on numerous public and private boards including, Chairman of Insite Vision (acquired by Sun Pharmaceuticals) and Edgemont Pharmaceuticals (acquired by Alvogen, Inc.) and currently serves on the boards of Adgero BioPharmaceuticals, Emisphere Technologies and QSpex Technologies Inc. He also is a Co-Founding Investor and Board member of Corino Therapeutics and the sole managing member of Texas Oncology Investments, LLC. Mr. McInerney received his BS in Pharmacy from St. John’s University in 1983 and also completed a post graduate residency in drug information systems at the New York University Medical Center.
Castle Hill Capital Partners, Inc.
Castle Hill offers an innovative and integrated offering centered on “Alpha and Assets.” The firm provides a range of brokerage solutions and strategic capital introduction support. Castle Hill works in partnership with our clients and is a trusted marketing adviser. The firm advocates and implements a structured marketing process that combines strategic marketing and specific, relevant investor introductions for a small set of differentiated alternative investment clients.
Castle Hill is a licensed broker-dealer, registered with the Securities and Exchange Commission (SEC) and is a member of The Financial Industry Regulatory Authority (FINRA), National Futures Association (NFA) and the Securities Investor Protection Corporation (SIPC). Additional information, including case studies about current client engagements and partner biographies, can be found at www.castlehillcap.com.
